TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24991995

Group type: EXPERIMENTAL
Intervention: 0.3mg/kg etomidate
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 2mg/kg propofol
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 4mg/kg thiopental
Number of subjects: 101
Study: 23201761

Group type: EXPERIMENTAL
Intervention: High intakes of meat (particularly high fat varieties) at age 18 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intakes of carbohydrate at age 18 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration less than six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early introduction of solids
Number of subjects: 0
Study: 20701400

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 3752

Group type: COMPARATOR
Intervention: Standard analgesic treatment
Number of subjects: 3752
Study: 18539007

Group type: EXPERIMENTAL
Intervention: 1 g/day of oral DHA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 2 g/day of oral DHA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 4 g/day of oral DHA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Plasma DHA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Plasma EPA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: n-6/n-3 ratio
Number of subjects: 35
Study: 15952173

Group type: EXPERIMENTAL
Intervention: TCR peptide vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplemental estrogen
Number of subjects: 0
Study: 11854727

Group type: EXPERIMENTAL
Intervention: WASA therapy (warfarin and aspirin)
Number of subjects: 402

Group type: COMPARATOR
Intervention: ASA therapy (aspirin alone)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: PTFE grafts
Number of subjects: 402

Group type: COMPARATOR
Intervention: Vein grafts
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: WASA therapy
Number of subjects: 402

Group type: COMPARATOR
Intervention: ASA therapy
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Vein grafts with WASA therapy
Number of subjects: 402

Group type: COMPARATOR
Intervention: Vein grafts with ASA therapy
Number of subjects: 402
Study: 10064286

Group type: EXPERIMENTAL
Intervention: Primary nursing care delivery system
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study: 7676796

Group type: EXPERIMENTAL
Intervention: Space blanket (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 50
Study: 2209656

Group type: EXPERIMENTAL
Intervention: Technetium 99m methoxyisobutylisonitrile (99mTc‐MIBI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thallium 201 (201Tl) chloride
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both agents (99mTc‐MIBI and 201Tl)
Number of subjects: 56
Study: 6934801

Group type: EXPERIMENTAL
Intervention: Alvogyl packing (Septodont, 1974)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 8
Study: 31985049

Group type: EXPERIMENTAL
Intervention: STS101 5.2 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: IM DHE
Number of subjects: 43

Group type: COMPARATOR
Intervention: Migranal
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: STS101 1.3 mg, 2.6 mg, 5.2 mg
Number of subjects: 43
Study: 30563778

Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Pridopidine 67.5 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Pridopidine 112.5 mg
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 28401414

Group type: EXPERIMENTAL
Intervention: Low masculinity feedback
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control feedback
Number of subjects: 285
Study: 26492402

Group type: EXPERIMENTAL
Intervention: Dose-escalated intensity-modulated radiotherapy (IMRT) after tumour excision
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Inverse-planned IMRT for selected non-trial patients
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: IMPORT HIGH trial protocol for target volume and OARs dose constraints
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Use of clip information for breast treatment verification
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: CT guided planning with full three-dimensional dose compensation
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Photon boost RT
Number of subjects: 1386
Study: 24041337

Group type: EXPERIMENTAL
Intervention: 12,000 IU of vitamin D3
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 24,000 IU of vitamin D3
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 48,000 IU of vitamin D3
Number of subjects: 375
Study: 21620725

Group type: COMPARATOR
Intervention: Normal fluid intake (NFI: 2 L/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High fluid intake (HFI: 4 L/day)
Number of subjects: 62
Study: 19499846

Group type: EXPERIMENTAL
Intervention: rifaximin 1200 mg/day
Number of subjects: 142

Group type: COMPARATOR
Intervention: metronidazole 750 mg/day
Number of subjects: 142
Study: 17550474

Group type: EXPERIMENTAL
Intervention: Households receiving soap and handwashing promotion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control households
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Households with thermotolerant coliforms detected
Number of subjects: 80

Group type: COMPARATOR
Intervention: Households without thermotolerant coliforms detected
Number of subjects: 80
Study: 15234855

Group type: EXPERIMENTAL
Intervention: Behavioural intervention (ten one-on-one counselling sessions followed by maintenance sessions every 3 months)
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 4295

Group type: COMPARATOR
Intervention: Standard condition (twice-yearly Project RESPECT individual counselling)
Number of subjects: 4295
Study: 12082261

Group type: EXPERIMENTAL
Intervention: ACE-inhibitor (Spirapril - 6 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Isradipin - 5 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Beta-1-blocker (Talinolol - 100 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Diuretic (Indapamide - 1.5 mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 82
Study: 9926187

Group type: COMPARATOR
Intervention: Oxycodone (0.03 mg/kg via PCA, max 3 times/hour, lock-out 10 min) with Paracetamol (1000 mg three times a day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oxycodone (0.03 mg/kg via PCA, max 3 times/hour, lock-out 10 min) with Ketoprofen (100 mg three times a day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.03 mg/kg via PCA)
Number of subjects: 45
Study: 7497485

Group type: EXPERIMENTAL
Intervention: Slow oscillating inflation (1 atmosphere/20 sec) and slow deflation (over 15 sec)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Rapid inflation (over 30 sec) and rapid deflation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Slow oscillating inflation (1 atmosphere/20 sec) and rapid deflation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Rapid inflation (over 30 sec) and slow deflation (over 15 sec)
Number of subjects: 136
Study: 1974382

Group type: EXPERIMENTAL
Intervention: Metoprolol OROS (14/190 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Slow-release (SR) metoprolol (200 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Long-acting (LA) propranolol (160 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7011110

Group type: EXPERIMENTAL
Intervention: 10 mg R 41 468 (acute intravenous administration)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 40 mg R 41 468 t.i.d. (oral treatment for 8 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: R 41 468 (oral maintenance therapy for 3 weeks)
Number of subjects: 23
Study: 30079636

Group type: EXPERIMENTAL
Intervention: Proposed biosimilar pegfilgrastim (LA‐EP2006)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Reference pegfilgrastim (Neulasta®)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Both biologics (Proposed biosimilar and Reference pegfilgrastim)
Number of subjects: 169
Study: 26731753

Group type: EXPERIMENTAL
Intervention: FTC/TDF or TDF as PrEP
Number of subjects: 9
Study: 24161221

Group type: EXPERIMENTAL
Intervention: Foster care intervention (family-centered foster care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual in the institution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Never-institutionalized group
Number of subjects: 0
Study: 22417717

Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 1981
Study: 21221501

Group type: EXPERIMENTAL
Intervention: Low-dose oral erythromycin (6 mg/kg/day, in four doses over ten days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no erythromycin)
Number of subjects: 70
Study: 17379117

Group type: EXPERIMENTAL
Intervention: Regional block team (398 cases)
Number of subjects: 927

Group type: COMPARATOR
Intervention: Usual care (529 cases)
Number of subjects: 927
Study: 15542792

Group type: EXPERIMENTAL
Intervention: Montelukast 4 or 5 mg once per day for 12 months
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo once per day for 12 months
Number of subjects: 549
Study: 12436341

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9831697

Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study: 7990323

Group type: EXPERIMENTAL
Intervention: CO2-laser and ultrasonic cavitation
Number of subjects: 283

Group type: COMPARATOR
Intervention: Commonly applied methods (control group)
Number of subjects: 283
Study: 2918846

Group type: EXPERIMENTAL
Intervention: Colestipol (15 g/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenofibrate (0.25 g/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Colestipol plus Fenofibrate
Number of subjects: 18
Study: 31898176

Group type: EXPERIMENTAL
Intervention: Physicians' agreement on the presence of hypoxic–ischemic brain injury (HIBI) on head CT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Individual physician agreement with the neuroradiologist
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physician agreement on the perceived severity of HIBI on head CT
Number of subjects: 10
Study: 31562945

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q2W
Number of subjects: 3003

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 3003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3003

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 3003
Study: 28217864

Group type: EXPERIMENTAL
Intervention: Physical therapist-prescribed exercise via Skype
Number of subjects: 12
Study: 26678626

Group type: EXPERIMENTAL
Intervention: Evacetrapib 130 mg daily in addition to standard medical therapy
Number of subjects: 12092

Group type: COMPARATOR
Intervention: Placebo daily in addition to standard medical therapy
Number of subjects: 12092
Study: 23148089

Group type: EXPERIMENTAL
Intervention: Stanford Arthritis Self‐Management Programme (ASMP)
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1125
Study: 21524261

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 28
Study: 18442621

Group type: EXPERIMENTAL
Intervention: Pedometer group (P)
Number of subjects: 70
Study: 17157756

Group type: EXPERIMENTAL
Intervention: Oxygen (4 L/min via nasal prongs)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Air (via nasal prongs)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oxygen (4 L/min via nasal prongs) in hypoxic patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Air (in hypoxic patients)
Number of subjects: 51
Study: 14743984

Group type: EXPERIMENTAL
Intervention: Soft tissue mobilization (STM) with proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 11409185

Group type: EXPERIMENTAL
Intervention: Troxerutin 150 mg and carbazochrome 1.5 mg, administered intramuscularly (one ampoule) twice daily for one week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbazochrome alone, administered intramuscularly (one ampoule) twice daily for one week
Number of subjects: 0
Study: 9506401

Group type: EXPERIMENTAL
Intervention: Internet Trials Service (ITS)
Number of subjects: 0
Study: 8220919

Group type: EXPERIMENTAL
Intervention: Flurbiprofen LAT (40 mg, applied via a non‐woven polyester‐backed patch, 12‐hourly over 14 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (non-medicated patch)
Number of subjects: 104
Study: 2832575

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg twice daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice daily) + Hydrochlorothiazide (25 mg twice daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily) + Atenolol (50 mg daily)
Number of subjects: 37
Study: 30701936

Group type: COMPARATOR
Intervention: Classical triple scheme of first-line ET (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day) for 10 days
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Classical triple scheme of ET with rebamipide (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day, rebamipide 100 mg 3 times a day) for 10 days
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Classical triple scheme of ET with prolonged rebamipide (same as group 2 for 10 days, then rebamipide continued for 20 days)
Number of subjects: 94
Study: 26809928

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block (USFNB)
Number of subjects: 77
Study: 26244602

Group type: EXPERIMENTAL
Intervention: Plant sterol (PS) consumption (2 g/day for 4 weeks)
Number of subjects: 10
Study: 23594991

Group type: EXPERIMENTAL
Intervention: AL-108
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 21723487

Group type: EXPERIMENTAL
Intervention: PACS-integrated decision support tool
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonintegrated decision support tool
Number of subjects: 48
Study: 19220533

Group type: EXPERIMENTAL
Intervention: Lifestyle alone
Number of subjects: 3893

Group type: EXPERIMENTAL
Intervention: One oral glucose-lowering agent
Number of subjects: 3893

Group type: EXPERIMENTAL
Intervention: Two oral glucose-lowering agents
Number of subjects: 3893

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 3893

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 3893
Study: 17014562

Group type: EXPERIMENTAL
Intervention: temocapril (1 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: losartan (12.5 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: combination therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: temocapril and losartan
Number of subjects: 43
Study: 15243735

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 141
Study: 10959739

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not involved in the prophylaxis phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg weekly for 4 weeks
Number of subjects: 0
Study: 9515404

Group type: EXPERIMENTAL
Intervention: Helium-neon (He-Ne) diode laser at a fluence of 1.2 J/cm
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control incisions (not specified)
Number of subjects: 52
Study: 7690382

Group type: EXPERIMENTAL
Intervention: Midodrine (2.5 mg intravenously)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Midodrine (M)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxilofrine (O)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 15
Study: 3724113

Group type: EXPERIMENTAL
Intervention: Direct language instruction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Interactive language instruction
Number of subjects: 44
Study: 29437614

Group type: EXPERIMENTAL
Intervention: Vaborbactam alone (250 to 2000 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Meropenem alone (1000 to 2000 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vaborbactam and Meropenem in combination
Number of subjects: 76
Study: 26317968

Group type: EXPERIMENTAL
Intervention: Home environment intervention to reduce television viewing and displace sugar-sweetened beverages with non-caloric beverages (n=25)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-intervention control group (n=15)
Number of subjects: 40
Study: 25489036

Group type: EXPERIMENTAL
Intervention: Performance-based financing
Number of subjects: 0
Study: 23204154

Group type: COMPARATOR
Intervention: Control diet with iron supplementation (SG)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pork-containing diet (PG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control diet (CG)
Number of subjects: 65
Study: 19707144

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) Fastrach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional suspension laryngoscope
Number of subjects: 40
Study: 18558665

Group type: EXPERIMENTAL
Intervention: Irinotecan/5-fluorouracil (IF)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Cisplatin/5-fluorouracil (CF)
Number of subjects: 333
Study: 15707491

Group type: EXPERIMENTAL
Intervention: Prolonged conservative treatment under supervision of the general practitioner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 12672914

Group type: EXPERIMENTAL
Intervention: 10 g of soy nuts delivering 6.6 mg daidzein and 9.8 mg genistein
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 g of soy nuts delivering 13.2 mg daidzein and 19.6 mg genistein
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 g of soy nuts delivering 26.4 mg daidzein and 39.2 mg genistein
Number of subjects: 10
Study: 10546147

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study: 8906369

Group type: EXPERIMENTAL
Intervention: HHV-6 infection in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adenoviruses (ADV) in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Syncytial respiratory virus (SRV) in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HSV-1 in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HHV-7 in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Family history of FC in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cytokines (IL 1 beta, TNF beta, GM-CSF) in children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Follow-up of children with FC (G1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: IgM and IgA levels in children with FC (G1)
Number of subjects: 65
Study: 8265876

Group type: EXPERIMENTAL
Intervention: Resistive loads increased from 0 to 24 cm H2O/l/s in 1, 3 or 6 steps or decreased in 6 steps
Number of subjects: 18
Study: 4005428

Group type: EXPERIMENTAL
Intervention: ATG plus androgen
Number of subjects: 121

Group type: COMPARATOR
Intervention: ATG plus placebo
Number of subjects: 121
Study: 31950923

Group type: EXPERIMENTAL
Intervention: 8 mg silodosin for 10 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: No silodosin uptake
Number of subjects: 76
Study: 30232854

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medication (Metformin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Simple lifestyle intervention
Number of subjects: 100
Study: 28281972

Group type: EXPERIMENTAL
Intervention: 30 Gy WBRT + simvastatin 80 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: 30 Gy WBRT
Number of subjects: 50
Study: 24872255

Group type: COMPARATOR
Intervention: Right ventricular apex (RVA) pacing (n = 20)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right ventricular mid-septum (RVS) pacing (n = 19)
Number of subjects: 39
Study: 22305843

Group type: EXPERIMENTAL
Intervention: Patients with perceived difficulties in sexual activity at 1 month after discharge
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Patients with perceived difficulties in sexual activity at 18 months after discharge
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Patients without difficulties at 1 month who developed difficulties during follow-up
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Factors associated with perceived difficulties in sexual activity
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Patients who perceive difficulties in sexual activity
Number of subjects: 792
Study: 20633931

Group type: EXPERIMENTAL
Intervention: Baseline Glaucoma Probability Score (GPS)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Moorfields regression analysis (MRA)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Stereometric parameters
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Photograph-based horizontal cup-to-disc ratio
Number of subjects: 438
Study: 18388038

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/d
Number of subjects: 39

Group type: COMPARATOR
Intervention: Aspirin 100 mg/d
Number of subjects: 39